Should HPV vaccine be given to men?

BMJ (Online)

Volumn 339, Issue 7726, 2009, Pages 872-

  Castle, Philip E ^a   Scarinci, Isabel ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; EDITORIAL; GENOTYPE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; PRIORITY JOURNAL; SCREENING; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT SELECTION; SEX FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 70350072343     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b4127     Document Type: Editorial

References (12)

1. Food and Drug Administration. Male indication for Gardasil. 2009. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM181361.pdf.
2. Kim JJ, Goldie SJ. Cost-effectiveness analysis of including boys in a human papillomavirus (HPV) vaccination programme in the United States. BMJ 2009;339:b3884.[Abstract/Free Full Text]
3. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009;27:5133-5141 [CrossRef][Web of Science][Medline]
4. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41.[Web of Science][Medline]
5. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep 2008;57:1100-1103[Medline]
6. National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR Morb Mortal Wkly Rep 2009;58:997-1001.[Medline]
7. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.[Abstract/Free Full Text] (Pubitemid 46148088)
8. Hull SC, Caplan AL. The case for vaccinating boys against human papillomavirus. Public Health Genomics 2009;12:362-367[CrossRef][Web of Science][Medline]
9. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-2654 [Abstract/Free Full Text] (Pubitemid 43920838)
10. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007;13:857-861[CrossRef][Web of Science][Medline] (Pubitemid 47038188)
11. Madan RP, Keller MJ, Herold BC. Prioritizing prevention of HIV and sexually transmitted infections: first- 11. generation vaginal microbicides. Curr Opin Infect Dis 2006;19:49-54.[Web of Science][Medline]
12. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101-2104[Free Full Text]